IRF2 and melanoma: In particular, we identified proteins that typically act either as a transcriptional repressor (E4F1) or activator (IRF2) as both preferentially binding the A-risk allele of rs3769823, and verified binding of both factors via ChIP in melanoma cells and primary melanocytes.